25.43 USD
+0.58 (+2.33%)
25.41 USD
-0.02 (-0.08%)
ChartMill assigns a Buy % Consensus number of 77% to ACAD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 29.41. This target is 15.65% above the current price.
ACAD was analyzed by 27 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about ACAD.
In the previous month the buy percentage consensus was at a similar level.
ACAD was analyzed by 27 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-02 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-11-17 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-06 | Needham | Maintains | Buy -> Buy |
| 2025-11-06 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-21 | Citigroup | Initiate | Buy |
| 2025-09-29 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-24 | Needham | Maintains | Buy -> Buy |
| 2025-09-11 | TD Cowen | Maintains | Buy -> Buy |
| 2025-09-09 | UBS | Maintains | Buy -> Buy |
| 2025-08-08 | UBS | Maintains | Buy -> Buy |
| 2025-08-07 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-08-07 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-07 | Goldman Sachs | Maintains | Sell -> Sell |
| 2025-07-24 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-06-26 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-06-26 | Needham | Reiterate | Buy -> Buy |
| 2025-06-26 | Oppenheimer | Maintains | Perform -> Perform |
| 2025-06-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-23 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-06-05 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-05-21 | Deutsche Bank | Upgrade | Hold -> Buy |
| 2025-05-20 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-19 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-05-19 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-05-19 | Needham | Maintains | Buy -> Buy |
| 2025-05-19 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-05-19 | Baird | Maintains | Outperform -> Outperform |
| 2025-05-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the price target for ACAD stock?
27 analysts have analysed ACAD and the average price target is 29.41 USD. This implies a price increase of 15.65% is expected in the next year compared to the current price of 25.43.
Can you provide the consensus rating for ACADIA PHARMACEUTICALS INC stock?
The consensus rating for ACADIA PHARMACEUTICALS INC (ACAD) is 77.037 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed ACADIA PHARMACEUTICALS INC (ACAD)?
The number of analysts covering ACADIA PHARMACEUTICALS INC (ACAD) is 27.